血浆CEA、CA72-4和CA125联合检测在卵巢癌诊断中应用价值

Plasma CEA, CA72-4 and CA125 combined detection in diagnosis of ovarian cancer value

目的:探讨癌胚抗原(CEA)、糖类抗原72-4(CA72-4)及糖类抗原125(CA125)联合检测在卵巢癌诊断中的应用评价。方法:对卵巢恶性肿瘤60例,良性肿瘤103例及70名健康体检者采用电化学发光法测定其血浆CEA、CA72-4及CA125的含量,并分析比较。结果:卵巢癌组与卵巢良性肿瘤组和健康对照组相比,其血浆CEA、CA72-4和CA125水平显著升高(P<0.05);卵巢癌组血浆CA125的阳性率与卵巢子宫内膜样肿瘤相比,差异无统计学意义(P>0.05),与其他良性肿瘤相比有统计学意义(P<0.05)。结论:肿瘤标志物CEA、CA72-4和CA125联合检测可以提高卵巢癌诊断的灵敏度,且对卵巢肿瘤的良、恶性辅助及鉴别诊断有一定的应用价值。

Objective To explore application value of united detection of tumor markers embryo carcinoma antigen(CEA),sugar antigen 72-4(CA72-4),and sugar antigen 125(CA125) in the diagnosis of ovarian cancer.Methods The content of plasma CEA,CA72-4,and CA125 of 60 cases of ovarian malignant tumor,103 cases of benign tumor,and 70 healthy normal controls were determined by using the electrochemical luminescence method and the data were comparatively analyzed.Results When ovarian cancer group and ovarian benign tumor group compared with healthy control group,it was found that plasma CEA,CA72-4,and CA125 levels were significantly increased(P<0.05).Compared with ovarian endometrioid tumors,the difference of the positive rate of plasma CA125 to ovarian cancer group was not statistically significant(P>0.05),and compared with other ovarian benign tumors,the difference was statistically significant(P <0.05).Conclusion The united detection of tumor markers CEA,CA72-4,and CA125 can improve the sensitivity of diagnosis of ovarian cancer,and have clinical application valuein differential diagnosis of benign and malignant ovarian tumors.